150 related articles for article (PubMed ID: 32183683)
1. Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma.
Kumar A; Bhatia R; Chawla P; Anghore D; Saini V; Rawal RK
Anticancer Agents Med Chem; 2020; 20(10):1158-1172. PubMed ID: 32183683
[TBL] [Abstract][Full Text] [Related]
2. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Krause G; Hassenrück F; Hallek M
Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
[TBL] [Abstract][Full Text] [Related]
3. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
Roskoski R
Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
[TBL] [Abstract][Full Text] [Related]
4. Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.
Eltantawy A; Vallejos X; Sebea E; Evans K
Ann Pharmacother; 2019 Sep; 53(9):954-958. PubMed ID: 30813760
[No Abstract] [Full Text] [Related]
5. Copanlisib for the treatment of adults with relapsed follicular lymphoma.
Magagnoli M; Carlo-Stella C; Santoro A
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):813-823. PubMed ID: 32576028
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
[TBL] [Abstract][Full Text] [Related]
7. Copanlisib in the treatment of non-Hodgkin lymphoma.
Narkhede M; Cheson BD
Future Oncol; 2020 Sep; 16(26):1947-1955. PubMed ID: 32658557
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
Kim JH; Kim WS; Park C
BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
[TBL] [Abstract][Full Text] [Related]
9. On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.
Morschhauser F; Machiels JP; Salles G; Rottey S; Rule SAJ; Cunningham D; Peyrade F; Fruchart C; Arkenau HT; Genvresse I; Liu L; Köchert K; Shen K; Kneip C; Peña CE; Grevel J; Zhang J; Cisternas G; Reschke S; Granvil C; Awada A
Mol Cancer Ther; 2020 Feb; 19(2):468-478. PubMed ID: 31619463
[TBL] [Abstract][Full Text] [Related]
10. Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation.
Okabe S; Tanaka Y; Tauchi T; Ohyashiki K
Ann Hematol; 2019 Mar; 98(3):723-733. PubMed ID: 30430191
[TBL] [Abstract][Full Text] [Related]
11. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946).
Scott WJ; Hentemann MF; Rowley RB; Bull CO; Jenkins S; Bullion AM; Johnson J; Redman A; Robbins AH; Esler W; Fracasso RP; Garrison T; Hamilton M; Michels M; Wood JE; Wilkie DP; Xiao H; Levy J; Stasik E; Liu N; Schaefer M; Brands M; Lefranc J
ChemMedChem; 2016 Jul; 11(14):1517-30. PubMed ID: 27310202
[TBL] [Abstract][Full Text] [Related]
12. Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives.
Munoz J; Follows GA; Nastoupil LJ
Target Oncol; 2021 May; 16(3):295-308. PubMed ID: 33687623
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
14. Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Cheson BD; O'Brien S; Ewer MS; Goncalves MD; Farooki A; Lenz G; Yu A; Fisher RI; Zinzani PL; Dreyling M
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):135-141. PubMed ID: 30584024
[TBL] [Abstract][Full Text] [Related]
15. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.
Patnaik A; Appleman LJ; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Weiss GJ; Sachdev JC; Chadha M; Fulk M; Ejadi S; Mountz JM; Lotze MT; Toledo FG; Chu E; Jeffers M; Peña C; Xia C; Reif S; Genvresse I; Ramanathan RK
Ann Oncol; 2016 Oct; 27(10):1928-40. PubMed ID: 27672108
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor.
García-Valverde A; Rosell J; Serna G; Valverde C; Carles J; Nuciforo P; Fletcher JA; Arribas J; Politz O; Serrano C
Mol Cancer Ther; 2020 Jun; 19(6):1289-1297. PubMed ID: 32371592
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
[TBL] [Abstract][Full Text] [Related]
18. PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma.
Sapon-Cousineau V; Sapon-Cousineau S; Assouline S
Curr Treat Options Oncol; 2020 Apr; 21(6):51. PubMed ID: 32356174
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors.
Raj A; Kumar A; Singh AK; Singh H; Thareja S; Kumar P
Anticancer Agents Med Chem; 2023; 23(9):1013-1047. PubMed ID: 36650627
[TBL] [Abstract][Full Text] [Related]
20. Validated HPLC-UV method for simultaneous quantification of phosphatidylinositol 3-kinase inhibitors, copanlisib, duvelisib and idelalisib, in rat plasma: Application to a pharmacokinetic study in rats.
Siddesh A; Sriram D; Zakkula A; Kumar R; Dittakavi S; Zainuddin M; Trivedi RK; Mullangi R
Biomed Chromatogr; 2021 Apr; 35(4):e5015. PubMed ID: 33125719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]